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OBJECTIVES: In developing new medicines, pharmaceutical companies face the 
complex and challenging task of choosing comparators, in the absence of clear 
and consistent guidance, in order to produce evidence that best meets diverse 
stakeholder needs. This lack of clear and consistent guidance has led to several 
high-profile cases in which HTA bodies rejected products receiving regulatory 
approval due to a lack of evidence relative to desired comparators. Our objective 
was to identify key issues in comparator selection and present case studies 
highlighting these issues. METHODS: We conducted a comprehensive search of 
the published and grey literature addressing comparator selection, including 
formal guidelines from major regulatory, HTA, and professional organizations, as 
well as case studies and published opinions. Three authors independently and 
qualitatively assessed the identified literature, and the final list of issues was 
agreed upon through team discussion and consensus. RESULTS: Key challenges 
in the selection of appropriate comparators include: 1) lack of a standard 
definition for “standard of care,” 2) concerns regarding off-label usage; 3) 
changes in requirements due to market dynamics; and 4) RCT design issues. We 
explore several of these challenges further with case studies. CONCLUSIONS: 
Due to challenges inherent in meeting diverse stakeholder needs, the selection 
of comparators is a complex and multi-faceted problem. The challenges we 
identified highlight the need for more uniformity and clarity among existing 
standards. In the context of ongoing external standard setting and 
harmonization efforts, organizations seeking to provide guidance around 
comparator selection should consider the issues described herein and work 
towards the common goal of a more transparent, harmonized process that 
optimizes the production of evidence that best meets the needs of all 
stakeholders.  
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HEALTH TECHNOLOGY ASSESSMENT LANDSCAPE OF BIOSIMILARS – 
APPROACHES TO EVALUATIONS AND RESULTS  
Andreykiv M1, Dahal D2 
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Hawthorne, NY, USA  
OBJECTIVES: Gain insight into how HTA agencies evaluate biosimilar products 
and understand implications for future biosimilars. METHODS: Step I: Manually 
search 60 health care agencies’ websites for reports evaluating biosimilars. Step 
II: Categorize reports by HTA type, scope and outcome. Step III: Using a 
standardized set of categorical criteria, investigate HTA agencies’ approaches to 
biosimilar treatment recommendations, across multiple therapeutic areas. 
RESULTS: We identified a total of 47 HTA reports evaluating biosimilars, of 
which 38 are Single Technology Assessments (STA) and 9 are class reviews or 
clinical guidelines. Except for one STA by AMWSG, all recommendations were 
positive and no agency recognized substantial differences in clinical efficacy or 
safety between original and biosimilar products. A major factor influencing the 
negative AMWSG recommendation was limitations in the economic model 
provided by the sponsor company. After reviewing HTA reports on biosimilars, it 
is apparent that different countries apply different strategies to evaluating 
biosimilars – In France (13 STAs), Scotland (7 STAs) and Sweden (6 STAs), each 
biosimilar was reviewed individually; in Netherlands, CVZ published a 
“Preference policy for biologics” classifying biological products as “similar” and 
therefore therapeutically interchangeable. KCE (Belgian HTA body) chose this 
same approach and is currently studying the advantages and barriers of using 
biosimilars in Belgium. CONCLUSIONS: HTA agencies that have reviewed each 
biosimilar product individually, assessing all the available data through the full 
HTA process, have acknowledged the comparable safety and efficacy of 
biosimilar products with the original molecule. However, some individual 
restrictions were made in terms of prescribing patterns or formulation type 
limitations. Although the standard HTA path for biosimilars is not fully defined, 
we can conclude from this evaluation that HTA agencies generally treat 
biosimilars as equivalent in safety and efficacy to originator products.  
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OBJECTIVES: The Morisky Medication Adherence Scale (MMAS) has been 
validated in patients with hypertension using classic test theory analyses. Item 
Response Theory (IRT) methods are an increasingly popular, sophisticated 
means of validation in health outcomes research. The current study examined 
psychometric properties of the eight-item MMAS (MMAS-8) among hypertensive 
patients, using IRT. METHODS: Data were used from the U.S. 2012 National 
Health and Wellness Survey (NHWS; N=71,141), a web-based survey of patients’ 
demographics, health care attitudes and health outcomes. Respondents 
reporting physician diagnosis of hypertension and currently taking a 
prescription medication for hypertension were included. Reliability and validity 
of the MMAS-8 were examined using both classic test theory (Cronbach’s alpha) 
and IRT (two-parameter graded response model) analyses. RESULTS: Among 
16,680 patients with hypertension, 54.21% were male, mean age was 60.88 (SD = 
12.74) and years since diagnosis were 13.40 (SD=10.82). Non-adherence behavior 
frequencies varied across items; “do you have difficulty remembering to take all 
your medicine?” (28.92% “yes”), “do you sometimes forget to take your 
medicine?” (21.97%), “do you feel hassled about sticking to your treatment plan?” 
(16.21%) and “cut back or stopped taking your medicine because you felt worse 
when you took it?” (4.76%). The MMAS-8 was adequately reliable (Cronbach’s 
a=0.71); however, improvement was seen with removal of the “did you take all 
your medicine yesterday?” item (a=0.73). The eight items varied in their 
discrimination (range: 0.53–3.09), and item location parameters reflected a large, 
high range of non-adherence (0.68–4.79), indicating that the item set 
discriminates best at higher levels of non-adherence. CONCLUSIONS: The 
MMAS-8 has adequate psychometric properties for evaluating non-adherence in 
patients with hypertension, with room for improvement by eliminating one item 
and adding items that discriminate at lower levels of non-adherence. IRT is a 
helpful means for evaluating the reliability and validity of the MMAS-8.  
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OBJECTIVES: The 25-item National Eye Institute Visual Function Questionnaire 
(NEI VFQ-25) is widely used to assess patient-reported visual functioning. 
Previously, the reliability and validity of the NEI VFQ-25 has been assessed in 
patients with neovascular age-related macular degeneration (AMD). Its 
measurement performance in other ocular indications, and in large pooled 
datasets, remains unclear. This study aimed to evaluate the psychometric 
properties of the NEI VFQ-25 in a large sample of patients across multiple retinal 
diseases. METHODS: Dataset included pooled baseline NEI VFQ-25 data from six 
clinical trials in diabetic macular edema (DME), macular edema from branch and 
central retinal vein occlusion (RVO), neovascular AMD, and myopic choroidal 
neovascularisation. Rasch analysis was conducted by assessing item fit validity, 
threshold targeting, item dependency, reliability and stability. RESULTS: 
Measurement performance was evaluated for 2487 person measurements (mean 
age: 64±9 (SD) years; gender: 53% male). Mixed psychometric properties of the 
NEI VFQ-25 were identified. Key strengths identified included a high Person 
Separation Index of 0.93 (suggesting good reliability), predominantly low residual 
correlations (suggesting minimal local dependency between items), and no 
statistically significant Differential Item Functioning (suggesting stability of 
scoring function across country, study and gender). Some potential psychometric 
limitations of the NEI VFQ-25 included disordered thresholds for 15 of the 25 
items, poor fit according to the Rasch model for several items, and mismatched 
distributions of person and item threshold locations. These limitations suggest 
sub-optimal item targeting, potential problems with conceptual clarity, lack of 
discrimination across some response options and a consistent ceiling effect 
across all indications. CONCLUSIONS: Rasch analysis of NEI VFQ-25 identified 
many positive characteristics of this widely used instrument. Several suboptimal 
characteristics, however, were also identified, suggesting that changes to the NEI 
VFQ-25 could be considered to improve its psychometric performance in clinical 
trials of retinal diseases.  
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OBJECTIVES: To develop a patient-reported outcome (PRO) measure to assess the 
key functional and lifestyle impacts of chronic low back pain (cLBP) through 
qualitative concept elicitation (CE) and cognitive interviews. METHODS: Adult 
patients (18-80 years) with clinical diagnoses of cLBP of non-malignant origin 
experiencing moderate to severe levels of pain intensity were recruited in the 
U.S., UK, and Germany. Trained interviewers conducted CE and cognitive 
interview sessions with participating patients using semi-structured interview 
guides. The CE interviews elicited spontaneous reports of symptoms and 
associated impacts, followed by further probed exploration to confirm concepts. 
Cognitive interviews evaluated the degree of patient comprehension of the items 
in the draft PRO measure. All interview sessions were audio recorded and 
transcribed. The CE interviews were coded for qualitative content analysis using 
Atlas.ti, and cognitive interview transcripts were summarized in cognitive report 
tables. RESULTS: Forty-three CE interviews were conducted (mean age: 48.6±13.0, 
53.5% female, 74.4% -White/Caucasian). Mean pain NRS score was 6.7±1.3. A total 
of 2,220 impact expressions were derived from the transcripts, representing 47 
different impact concepts. Data from CE interviews was considered alongside 
existing measures, published literature and expert opinion to develop a 15-item 
draft instrument. Thirty additional patients participated in four waves of 
cognitive interviews, during which two items were removed and others were 
substantially modified to create the Pain Assessment for Low Back Impacts (PAL-
I). CONCLUSIONS: The PAL-I is a 13-item PRO measure for assessing lifestyle and 
functional impacts of cLBP that has been developed through direct qualitative 
patient involvement in accordance with the FDA’s PRO Guidance and scientific 
best practices. Cognitive interviews have provided evidence from patients that 
the measure is comprehensive, relevant to their cLBP experience, 
comprehendible, and easy to complete. The measure will be further tested in 
additional qualitative and quantitative studies to evaluate its measurement 
properties.  
